further excluded 1,127,077 measurements recorded as binned into 5 systolic and 7 diastolic BP ranges (e.g., systolic BP recorded in the range 140-159); this was an early recording method prior to the full EHR implementation in 2006. After noting that 75.6% of the 1,919,532 remaining measurements were from IM visits, we excluded the 188,173 OB/GYN and 280,501 other departmental measurements to obtain the most homogeneous BP phenotype, resulting in 1,450,858 measurements from IM visits on 107,196 individuals. Finally, after excluding those failing genotyping, 1,342,814 independent SBP and DBP IM visit measurements from different days (345,031 untreated and 997,783 treated) on 99,785 individuals obtained from the beginning of 2006 to the end of 2011 remained for analysis. Anti-hypertensive medication treatment was assessed via EHR prescription filling information; once an individual started a drug, they were considered treated on all subsequent measurements. We added 15mmHg to treated SBP values and 10mmHg to treated DBP values,47 similar to previous BP GWAS,17 to correct for treatment effect.
